QTc interval. Avoid or Use Alternate Drug.pentobarbitalMinor (1)pentobarbital will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.perindoprilMonitor Closely (1)perindopril, alfuzosin. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.perphenazineMonitor Closely (2)perphenazine and alfuzosin both increase QTc interval. Use Caution/Monitor. alfuzosin and perphenazine both increase QTc interval. Use Caution/Monitor.phenobarbitalMinor (1)phenobarbital will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.phenoxybenzamineMonitor Closely (1)alfuzosin and phenoxybenzamine both increase anti-hypertensive channel blocking. Use Caution/Monitor.phentolamineMonitor Closely (1)alfuzosin and phentolamine both increase anti-hypertensive channel blocking. Use Caution/Monitor.phenylephrineMinor (1)alfuzosin, phenylephrine. Either decreases effects of the other by Mechanism: pharmacodynamic antagonism. Minor/Significance Unknown.phenylephrine POMinor (1)alfuzosin, phenylephrine PO. Either decreases effects of the other by Mechanism: pharmacodynamic antagonism. Minor/Significance Unknown.phenytoinMinor (1)phenytoin will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.pimavanserinMonitor Closely (1)pimavanserin and alfuzosin both increase QTc interval. Use Caution/Monitor.Serious - Use Alternative (1)alfuzosin and pimavanserin both increase QTc interval. Avoid or Use Alternate Drug.pimozideMonitor Closely (1)pimozide and alfuzosin both increase QTc interval. Use Caution/Monitor.Serious - Use Alternative (1)alfuzosin and pimozide both increase QTc interval. Contraindicated.pindololMonitor Closely (1)alfuzosin and pindolol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.piroxicamMonitor Closely (1)piroxicam decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.pitolisantMonitor Closely (1)pitolisant and alfuzosin both increase QTc interval. Use Caution/Monitor.Serious - Use Alternative (1)alfuzosin and pitolisant both increase QTc interval. Avoid or Use Alternate Drug.ponesimodSerious - Use Alternative (1)alfuzosin and ponesimod both increase QTc interval. Avoid or Use Alternate Drug.posaconazoleContraindicated (1)alfuzosin and posaconazole both increase QTc interval. Contraindicated.Monitor Closely (1)posaconazole and alfuzosin both increase QTc interval. Use Caution/Monitor.Minor (1)posaconazole will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.prazosinMonitor Closely (1)alfuzosin and prazosin both increase anti-hypertensive channel blocking. Use Caution/Monitor.prednisoneMinor (1)prednisone will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.primaquineMonitor Closely (1)alfuzosin and primaquine both increase QTc interval. Use Caution/Monitor.primidoneMinor (1)primidone will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.procainamideMonitor Closely (1)procainamide and alfuzosin both increase QTc interval. Use Caution/Monitor.Serious - Use Alternative (1)alfuzosin and procainamide both increase QTc interval. Avoid or Use Alternate Drug.propafenoneMonitor Closely (1)propafenone and alfuzosin both increase QTc interval. Use Caution/Monitor.Serious - Use Alternative (1)alfuzosin and propafenone both increase QTc interval. Avoid or Use Alternate Drug.propranololMonitor Closely (1)alfuzosin and propranolol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely. The severity and duration of hypotension following the first dose of Alfuzosin may be enhanced.protriptylineMonitor Closely (2)protriptyline and alfuzosin both increase QTc interval. Use Caution/Monitor. alfuzosin and protriptyline both increase QTc interval. Use Caution/Monitor.pseudoephedrineMonitor Closely (1)pseudoephedrine decreases effects of alfuzosin by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.quetiapineMonitor Closely (1)quetiapine and alfuzosin both increase QTc interval. Use Caution/Monitor.Serious - Use Alternative (1)alfuzosin and quetiapine both increase QTc interval. Avoid or Use Alternate Drug.quinaprilMonitor Closely (1)quinapril, alfuzosin. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.quinidineMonitor Closely (1)quinidine and alfuzosin both increase QTc interval. Use Caution/Monitor.Serious - Use Alternative (1)alfuzosin and quinidine both increase QTc interval. Avoid or Use Alternate Drug.quinineSerious - Use Alternative (1)alfuzosin and quinine both increase QTc interval. Avoid or Use Alternate Drug.quinupristin/dalfopristinMinor (1)quinupristin/dalfopristin will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.ramiprilMonitor Closely (1)ramipril, alfuzosin. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.ranolazineMonitor Closely (2)ranolazine and alfuzosin both increase QTc interval. Use Caution/Monitor. alfuzosin and ranolazine both increase QTc interval. Use Caution/Monitor.ribociclibMonitor Closely (2)ribociclib and alfuzosin both increase QTc interval. Use Caution/Monitor. ribociclib will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.Serious - Use Alternative (1)alfuzosin and ribociclib both increase QTc interval. Contraindicated.rifabutinMonitor Closely (1)rifabutin will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.rifampinMonitor Closely (1)rifampin will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.rifapentineMinor (1)rifapentine will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.rilpivirineMonitor Closely (2)rilpivirine and alfuzosin both increase QTc interval. Use Caution/Monitor. alfuzosin and rilpivirine both increase QTc interval. Use Caution/Monitor.risperidoneMonitor Closely (2)risperidone and alfuzosin both increase QTc interval. Use Caution/Monitor. alfuzosin and risperidone both increase QTc interval. Use Caution/Monitor.ritonavirContraindicated (1)ritonavir will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.romidepsinMonitor Closely (2)romidepsin and alfuzosin both increase QTc interval. Use Caution/Monitor. alfuzosin and romidepsin both increase QTc interval. Use Caution/Monitor.rucaparibMonitor Closely (1)rucaparib will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Adjust dosage of CYP3A4 substrates, if clinically indicated.rufinamideMinor (1)rufinamide will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.salicylates (non-asa)Monitor Closely (1)salicylates (non-asa) decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.salmeterolMonitor Closely (1)alfuzosin and salmeterol both increase QTc interval. Use Caution/Monitor.salsalateMonitor Closely (1)salsalate decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.saquinavirContraindicated (2)saquinavir increases levels of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Potential for increased toxicity. . alfuzosin and saquinavir both increase QTc interval. Contraindicated.Monitor Closely (1)saquinavir and alfuzosin both increase QTc interval. Use Caution/Monitor.secobarbitalMinor (1)secobarbital will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.selpercatinibMonitor Closely (1)selpercatinib and alfuzosin both increase QTc interval. Use Caution/Monitor.sertralineMonitor Closely (2)sertraline and alfuzosin both increase QTc interval. Use Caution/Monitor. alfuzosin and sertraline both increase QTc interval. Use Caution/Monitor.sevofluraneSerious - Use Alternative (1)alfuzosin and sevoflurane both increase QTc interval. Avoid or Use Alternate Drug.sildenafilSerious - Use Alternative (1)sildenafil increases effects of alfuzosin by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of hypotension; separate sildenafil >25mg from alpha blocker by 4hr.silodosinMonitor Closely (1)alfuzosin and silodosin both increase anti-hypertensive channel blocking. Use Caution/Monitor.siponimodSerious - Use Alternative (1)alfuzosin and siponimod both increase QTc interval. Avoid or Use Alternate Drug.solifenacinMonitor Closely (2)solifenacin and alfuzosin both increase QTc interval. Use Caution/Monitor. alfuzosin and solifenacin both increase QTc interval. Use Caution/Monitor.sorafenibMonitor Closely (1)sorafenib and alfuzosin both increase QTc interval. Use Caution/Monitor.Serious - Use Alternative (1)alfuzosin and sorafenib both increase QTc interval. Avoid or Use Alternate Drug.sotalolMonitor Closely (2)sotalol and alfuzosin both increase QTc interval. Use Caution/Monitor. alfuzosin and sotalol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely. The severity and duration of hypotension following the first dose of Alfuzosin may be enhanced.Serious - Use Alternative (1)alfuzosin and sotalol both increase QTc interval. Avoid or Use Alternate Drug.St John's WortMonitor Closely (1)St John's Wort will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.stiripentolMonitor Closely (1)stiripentol, alfuzosin. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Stiripentol is a CYP3A4 inhibitor and inducer. Monitor CYP3A4 substrates coadministered with stiripentol for increased or decreased effects. CYP3A4 substrates may require dosage adjustment.sulfasalazineMonitor Closely (1)sulfasalazine decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.sulindacMonitor Closely (1)sulindac decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.sunitinibMonitor Closely (2)sunitinib and alfuzosin both increase QTc interval. Use Caution/Monitor. alfuzosin and sunitinib both increase QTc interval. Use Caution/Monitor.tacrolimusMonitor Closely (2)tacrolimus and alfuzosin both increase QTc interval. Use Caution/Monitor. alfuzosin and tacrolimus both increase QTc interval. Use Caution/Monitor.tadalafilMonitor Closely (1)tadalafil increases effects of alfuzosin by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.tamsulosinSerious - Use Alternative (1)alfuzosin, tamsulosin. Either increases effects of the other by additive vasodilation. Avoid or Use Alternate Drug. Risk of hypotension.tazemetostatMonitor Closely (1)tazemetostat will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.tecovirimatMonitor Closely (1)tecovirimat will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Tecovirimat is a weak CYP3A4 inducer. Monitor sensitive CYP3A4 substrates for effectiveness if coadministered.telavancinMonitor Closely (2)telavancin and alfuzosin both increase QTc interval. Use Caution/Monitor. alfuzosin and telavancin both increase QTc interval. Use Caution/Monitor.terazosinMonitor Closely (1)alfuzosin and terazosin both increase anti-hypertensive channel blocking. Use Caution/Monitor.tetrabenazineMonitor Closely (1)tetrabenazine and alfuzosin both increase QTc interval. Use Caution/Monitor.Serious - Use Alternative (1)alfuzosin and tetrabenazine both increase QTc interval. Avoid or Use Alternate Drug.thioridazineContraindicated (1)alfuzosin and thioridazine both increase QTc interval. Contraindicated.Monitor Closely (1)thioridazine and alfuzosin both increase QTc interval. Use Caution/Monitor.timololMonitor Closely (1)alfuzosin and timolol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.tipranavirContraindicated (1)tipranavir increases levels of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Potential for increased toxicity. Tipranavir is used with ritonavir (boosted therapy) which is a potent CYP3A4 inhibitor.tizanidineMinor (1)tizanidine increases effects of alfuzosin by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypotension.tolfenamic acidMonitor Closely (1)tolfenamic acid decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.tolmetinMonitor Closely (1)tolmetin decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.topiramateMinor (1)topiramate will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.toremifeneMonitor Closely (1)toremifene and alfuzosin both increase QTc interval. Use Caution/Monitor.Serious - Use Alternative (1)alfuzosin and toremifene both increase QTc interval. Avoid or Use Alternate Drug. Concurrent use of toremifene with agents causing QT prolongation should be avoided. If concomitant use is required it's recommended that toremifene be interrupted. If interruption not possible, patients requiring therapy with a drug that prolongs QT should be closely monitored. ECGs should be obtained for high risk patients.trandolaprilMonitor Closely (1)trandolapril, alfuzosin. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.treprostinilMinor (1)treprostinil increases effects of alfuzosin by pharmacodynamic synergism. Minor/Significance Unknown.triclabendazoleMonitor Closely (1)alfuzosin and triclabendazole both increase QTc interval. Use Caution/Monitor.trimipramineMonitor Closely (2)trimipramine and alfuzosin both increase QTc interval. Use Caution/Monitor. alfuzosin and trimipramine both increase QTc interval. Use Caution/Monitor.triptorelinMonitor Closely (1)triptorelin and alfuzosin both increase QTc interval. Use Caution/Monitor.umeclidinium bromide/vilanterol inhaledSerious - Use Alternative (1)alfuzosin and umeclidinium bromide/vilanterol inhaled both increase QTc interval. Avoid or Use Alternate Drug. Exercise extreme caution when vilanterol coadministered with drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be potentiatedvalbenazineMonitor Closely (1)valbenazine and alfuzosin both increase QTc interval. Use Caution/Monitor.vandetanibMonitor Closely (1)vandetanib and alfuzosin both increase QTc interval. Use Caution/Monitor.Serious - Use Alternative (1)alfuzosin and vandetanib both increase QTc interval. Avoid or Use Alternate Drug.vardenafilMonitor Closely (2)vardenafil and alfuzosin both increase QTc interval. Use Caution/Monitor. alfuzosin and vardenafil both increase QTc interval. Use Caution/Monitor.Serious - Use Alternative (1)vardenafil increases effects of alfuzosin by pharmacodynamic synergism. Contraindicated. Risk of hypotension.vemurafenibMonitor Closely (1)vemurafenib and alfuzosin both increase QTc interval. Use Caution/Monitor.Serious - Use Alternative (1)alfuzosin and vemurafenib both increase QTc interval. Avoid or Use Alternate Drug.verapamilMonitor Closely (1)alfuzosin and verapamil both increase anti-hypertensive channel blocking. Use Caution/Monitor.Minor (1)verapamil will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.vilanterol/fluticasone furoate inhaledSerious - Use Alternative (1)alfuzosin and vilanterol/fluticasone furoate inhaled both increase QTc interval. Avoid or Use Alternate Drug. Exercise extreme caution when vilanterol coadministered with drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be potentiatedvoclosporinMonitor Closely (1)voclosporin, alfuzosin. Either increases effects of the other by QTc interval. Use Caution/Monitor.voriconazoleContraindicated (1)alfuzosin and voriconazole both increase QTc interval. Contraindicated.Monitor Closely (1)voriconazole and alfuzosin both increase QTc interval. Use Caution/Monitor.Minor (1)voriconazole will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.vorinostatMonitor Closely (2)vorinostat and alfuzosin both increase QTc interval. Use Caution/Monitor. alfuzosin and vorinostat both increase QTc interval. Use Caution/Monitor.voxelotorSerious - Use Alternative (1)voxelotor will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Voxelotor increases systemic exposure of sensitive CYP3A4 substrates. Avoid coadministration with sensitive CYP3A4 substrates with a narrow therapeutic index. Consider dose reduction of the sensitive CYP3A4 substrate(s) if unable to avoid.yohimbeSerious - Use Alternative (1)yohimbe increases effects of alfuzosin by pharmacodynamic synergism. Contraindicated.zafirlukastMinor (1)zafirlukast will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.ziprasidoneMonitor Closely (1)ziprasidone and alfuzosin both increase QTc interval. Use Caution/Monitor.Serious - Use Alternative (1)alfuzosin and ziprasidone both increase QTc interval. Avoid or Use Alternate Drug.zotepineMonitor Closely (1)alfuzosin and zotepine both increase anti-hypertensive channel blocking. Use Caution/Monitor. 1-10% Abdominal pain (1-2%) Back pain (1-2%) Brochitis (1-2%) Constipation (1-2%) Dizziness (5.7%) Dyspepsia (1-2%) Fatigue (2.7%) Headache (3%) Impotence (1-2%) Nausea (1-2%) Pharyngitis (1-2%) URT infection (3%) Sinusitis (1-2%) Upper respiratory infection (3%) Postmarketing Reports General disorders: Edema Cardiac disorders: Tachycardia, chest pain, angina pectoris in patients with pre-existing coronary artery disease, atrial